Clinical Trials

Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT02772588 2026-01-27

AASUR in High Risk Prostate Cancer

Phase 2 Completed

64 enrolled

Prostatic Neoplasms

NCT03556904 2026-01-15

FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)

Phase 2 Completed

14 enrolled 16 charts

Prostatic Neoplasms

NCT06592924 2026-01-14

TRIPLE-SWITCH

Phase 3 Recruiting

830 enrolled

Adenocarcinoma, Prostatic Neoplasms

NCT04647526 2026-01-13

SPLASH

455 enrolled 18 charts

Prostatic Neoplasms

NCT01995058 2026-01-08

Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC

Phase 2 Terminated

54 enrolled 11 charts

Prostatic Neoplasms

NCT06384222 2025-12-30

Hyperpolarized (HP) 13C Pyruvate Magnetic Resonance Imaging (MRI) for Response Monitoring to Neoadjuvant Abiraterone

32 enrolled

Prostatic Neoplasms

NCT06378866 2025-12-26

DIVINE

532 enrolled

Phase 1 Active not recruiting

Prostatic Neoplasms

NCT06421935 2025-12-19

M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)

141 enrolled

Gynecologic

Ovarian Neoplasms

NCT04175431 2025-12-18

Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study

100 enrolled

Prostate Adenocarcinoma

NCT04446117 2025-12-18

CONTACT-02

575 enrolled 13 charts

Phase EARLY_PHASE1 Active not recruiting

Prostatic Neoplasms

NCT03511196 2025-12-04

Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer

17 enrolled

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT05189457 2025-12-04

First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer

32 enrolled

Prostatic Neoplasms

NCT01961843 2025-11-25

Abiraterone Acetate for Castrate Resistant Prostate Cancer

Phase NA Completed

40 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Prostatic Neoplasms

NCT05914116 2025-11-21

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

Phase 1/2 Recruiting

862 enrolled

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Prostatic Neoplasms, Small Cell Lung Carcinoma

NCT03480646 2025-10-29

ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer

Phase 1/2 Completed

175 enrolled 23 charts

Tumor-Agnostic

Neoplasms

NCT02711137 2025-10-21

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Phase 1/2 Terminated

137 enrolled 31 charts

BreastCNSGastrointestinalGenitourinaryGynecologicLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Primary Myelofibrosis

NCT05733351 2025-09-15

Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer

Phase 1 Terminated

4 enrolled

Prostatic Neoplasms

NCT06145308 2025-09-15

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

Phase 2 Active not recruiting

39 enrolled

Head & Neck

Salivary Gland Neoplasms

NCT03860987 2025-09-08

Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer

12 enrolled

Castrate Sensitive Prostate Cancer

NCT04666129 2025-08-17

Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer

Phase 1 Completed

48 enrolled

Metastatic Castration-Resistant Prostate Cancer

NCT03298087 2025-08-01

Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer

Phase 2 Completed

28 enrolled 10 charts

Newly Diagnosed Oligometastatic Prostate Cancer

NCT05204927 2025-07-31

177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer

439 enrolled

Prostatic Neoplasms

NCT05177042 2025-07-25

Trial of ARV-110 and Abiraterone in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Phase 1 Completed

45 enrolled

Prostatic Neoplasms

NCT05288166 2025-06-27

CYCLONE 3

925 enrolled 12 charts

Neoplasm Metastasis, Prostatic Neoplasms, Urogenital Neoplasms

NCT03072238 2025-06-06

IPATential150

Phase 3 Completed

1,101 enrolled 35 charts

Prostatic Neoplasms

NCT01848067 2025-05-04

Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer

Phase 1/2 Completed

9 enrolled 9 charts

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT04262154 2025-04-27

Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer

28 enrolled

Prostatic Neoplasms

NCT03903835 2025-04-09

ProBio

Phase 3 Recruiting

750 enrolled